Enzon Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Enzon Pharmaceuticals's earnings have been declining at an average annual rate of -50.9%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 69.6% per year.
Key information
-50.9%
Earnings growth rate
-52.4%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -69.6% |
| Return on equity | 2.2% |
| Net Margin | -926.9% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Enzon Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | 0 | 1 | 0 |
| 30 Jun 23 | 0 | -1 | 1 | 0 |
| 31 Mar 23 | 0 | -1 | 1 | 0 |
| 31 Dec 22 | 0 | -1 | 1 | 0 |
| 30 Sep 22 | 0 | -3 | 1 | 0 |
| 30 Jun 22 | 0 | -3 | 1 | 0 |
| 31 Mar 22 | 0 | -3 | 1 | 0 |
| 31 Dec 21 | 1 | -2 | 1 | 0 |
| 30 Sep 21 | 1 | -3 | 1 | 0 |
| 30 Jun 21 | 1 | -2 | 2 | 0 |
| 31 Mar 21 | 0 | -2 | 1 | 0 |
| 31 Dec 20 | 0 | -2 | 1 | 0 |
| 30 Sep 20 | 0 | -1 | 1 | 0 |
| 30 Jun 20 | 0 | -1 | 1 | 0 |
| 31 Mar 20 | 0 | -1 | 1 | 0 |
| 31 Dec 19 | 0 | -1 | 1 | 0 |
| 30 Sep 19 | 7 | 6 | 1 | 0 |
| 30 Jun 19 | 7 | 6 | 1 | 0 |
| 31 Mar 19 | 7 | 6 | 1 | 0 |
| 31 Dec 18 | 7 | 6 | 1 | 0 |
| 30 Sep 18 | 0 | -1 | 1 | 0 |
| 30 Jun 18 | 0 | 0 | 1 | 0 |
| 31 Mar 18 | 7 | 4 | 1 | 0 |
| 31 Dec 17 | 8 | 5 | 1 | 0 |
| 30 Sep 17 | 9 | 0 | 1 | 0 |
| 30 Jun 17 | 11 | 1 | 1 | 0 |
| 31 Mar 17 | 7 | -2 | 1 | 0 |
| 31 Dec 16 | 8 | -1 | 2 | 0 |
| 30 Sep 16 | 11 | 16 | 2 | 0 |
| 30 Jun 16 | 12 | 13 | 2 | 0 |
| 31 Mar 16 | 15 | 16 | 2 | 0 |
| 31 Dec 15 | 17 | 22 | 2 | 0 |
| 30 Sep 15 | 20 | 15 | 1 | 0 |
| 30 Jun 15 | 25 | 24 | 2 | 0 |
| 31 Mar 15 | 27 | 27 | 2 | 0 |
| 31 Dec 14 | 31 | 29 | 2 | 0 |
| 30 Sep 14 | 32 | 28 | 4 | 0 |
| 30 Jun 14 | 33 | 26 | 5 | 1 |
| 31 Mar 14 | 33 | 24 | 6 | 1 |
| 31 Dec 13 | 34 | 18 | 9 | 3 |
| 30 Sep 13 | 39 | 8 | 10 | 7 |
| 30 Jun 13 | 41 | 6 | 11 | 10 |
| 31 Mar 13 | 42 | 1 | 13 | 15 |
Quality Earnings: EZ1 is currently unprofitable.
Growing Profit Margin: EZ1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EZ1 is unprofitable, and losses have increased over the past 5 years at a rate of 50.9% per year.
Accelerating Growth: Unable to compare EZ1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EZ1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: EZ1 has a negative Return on Equity (2.22%), as it is currently unprofitable.